#1 Clinical Trials Search in Europe

Deferiprone

Deferiprone, an oral iron chelator, has been the subject of numerous clinical trials investigating its efficacy and safety in treating various conditions. These trials have explored its use in iron overload disorders, neurodegenerative diseases, and even HIV infection. This article summarizes key findings from clinical trials using deferiprone, providing insights into its potential therapeutic applications and safety profile.

Table of Contents

What is Deferiprone?

Deferiprone is a medication primarily used to treat iron overload in the body. It’s also known by its brand name Ferriprox[1]. Other names for deferiprone include L1 and DFP[2]. This drug belongs to a class of medications called iron chelators, which means it helps remove excess iron from the body[3].

Conditions Treated by Deferiprone

Deferiprone is used to treat several conditions related to iron overload:

  • Thalassemia: A blood disorder that causes the body to make less hemoglobin than normal[1].
  • Sickle Cell Disease: An inherited red blood cell disorder[1].
  • Other Anemias: Various conditions where there aren’t enough healthy red blood cells to carry oxygen throughout the body[1].
  • Pantothenate Kinase-Associated Neurodegeneration (PKAN): A rare genetic disorder that causes iron to accumulate in the brain[3].

In these conditions, patients often require frequent blood transfusions, which can lead to iron buildup in the body over time. Deferiprone helps remove this excess iron[4].

How Deferiprone Works

Deferiprone works by binding to excess iron in the body, forming a compound that can be easily excreted through urine. This process is called “chelation.” By removing excess iron, deferiprone helps prevent organ damage that can occur when too much iron accumulates in the body[1].

Different Formulations of Deferiprone

Deferiprone comes in several forms:

  • Immediate-release tablets: These are the standard form of the medication[5].
  • Extended-release tablets: These release the medication more slowly in the body[5].
  • Oral solution: A liquid form of the medication, which may be easier for some patients to take[4].

Dosage and Administration

The dosage of deferiprone can vary depending on the condition being treated and the individual patient. Some common dosages include:

  • 75-100 mg/kg of body weight per day, divided into three doses[4].
  • 20-60 mg/kg of body weight per day, divided into two or three doses[6].

It’s important to take deferiprone exactly as prescribed by your doctor. The medication can be taken with or without food, depending on your doctor’s instructions[7].

Side Effects and Safety Considerations

Like all medications, deferiprone can cause side effects. Some common side effects include:

  • Nausea and vomiting
  • Abdominal pain
  • Joint pain (arthralgia)
  • Changes in liver function tests
  • Neutropenia: A decrease in white blood cells, which can increase the risk of infections[7]

A rare but serious side effect is agranulocytosis, a severe decrease in white blood cells. Your doctor will monitor your blood counts regularly while you’re taking deferiprone[7].

Patients with kidney problems may need their dose adjusted, as the medication is primarily excreted through the kidneys[2].

Ongoing Research and Potential New Uses

Researchers are exploring the use of deferiprone for other conditions:

  • Friedreich’s Ataxia: A genetic disorder that affects the nervous system[6].
  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord[8].
  • HIV infection: Some studies are looking at whether deferiprone might have antiviral effects[9].

These potential new uses are still being studied, and deferiprone is not yet approved for treating these conditions.

Condition Key Findings Dosage Formulation
Iron Overload in Thalassemia and Sickle Cell Disease Effective in reducing serum ferritin levels and liver iron concentration 75-100 mg/kg/day Oral solution, immediate-release tablets
Pantothenate Kinase-Associated Neurodegeneration (PKAN) Compassionate use program for patients who completed previous trials Variable, based on previous trial doses Oral solution
Friedreich’s Ataxia Investigated safety, tolerability, and potential efficacy in neurological symptoms 20-60 mg/kg/day Oral solution
Myelodysplastic Syndrome (MDS) Studied effects on oxidative stress and iron overload in transfusion-dependent patients Up to 100 mg/kg/day Not specified
HIV Infection Investigated potential antiretroviral activity and safety in asymptomatic HIV-infected subjects 99-150 mg/kg/day Not specified

FAQ

  • What is deferiprone and how does it work? Deferiprone is an oral iron chelator that binds to excess iron in the body, forming a complex that can be excreted. It is primarily used to treat iron overload conditions, such as those resulting from frequent blood transfusions.
  • In which conditions has deferiprone been studied? Clinical trials have investigated deferiprone in various conditions, including iron overload in thalassemia and sickle cell disease, neurodegenerative disorders like Friedreich's ataxia and pantothenate kinase-associated neurodegeneration (PKAN), and even in HIV infection.
  • What are the common side effects of deferiprone? Common side effects reported in clinical trials include gastrointestinal issues (nausea, vomiting, abdominal pain), joint pain, and changes in liver enzyme levels. The most serious potential side effect is severe neutropenia, a significant decrease in white blood cells.
  • How is deferiprone administered? Deferiprone is typically administered orally, either as tablets or as an oral solution. The dosage and frequency may vary depending on the specific condition being treated and the formulation used (immediate-release or extended-release).
  • Are there ongoing studies to improve deferiprone's formulation? Yes, several clinical trials have explored new formulations of deferiprone, including extended-release tablets and sustained-release formulations. These studies aim to improve the drug's pharmacokinetic profile and potentially reduce dosing frequency.

Ongoing Clinical Trials on Deferiprone

  • Studying the Effects of Deferiprone on Motor Function in Children with Pelizaeus-Merzbacher Disease

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Deferiprone for Preventing Secondary Degeneration in Stroke Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Iron chelator: A substance that binds to iron in the body, allowing it to be removed. Deferiprone is an example of an iron chelator used to treat iron overload conditions.
  • Serum ferritin: A blood protein that contains iron and is used as an indicator of the body's iron stores. High levels may indicate iron overload.
  • Thalassemia: An inherited blood disorder that causes the body to produce less hemoglobin than normal, often resulting in anemia and iron overload due to frequent blood transfusions.
  • Friedreich's ataxia: A rare genetic disease that causes progressive damage to the nervous system, resulting in movement problems. It may also involve iron accumulation in certain tissues.
  • Pantothenate kinase-associated neurodegeneration (PKAN): A rare inherited disorder characterized by progressive difficulty with movement and iron accumulation in the brain.
  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Labile plasma iron (LPI): A form of non-transferrin-bound iron in the blood that can cause oxidative damage to cells and tissues.
  • Oxidative stress: An imbalance between free radicals and antioxidants in the body, which can lead to cell and tissue damage. Excess iron can contribute to oxidative stress.
  • Myelodysplastic syndrome (MDS): A group of disorders characterized by ineffective production of blood cells, often requiring frequent blood transfusions which can lead to iron overload.

References

  1. https://clinicaltrials.gov/study/NCT02443545
  2. https://clinicaltrials.gov/study/NCT01770652
  3. https://clinicaltrials.gov/study/NCT02635841
  4. https://clinicaltrials.gov/study/NCT00529152
  5. https://clinicaltrials.gov/study/NCT02465489
  6. https://clinicaltrials.gov/study/NCT00530127
  7. https://clinicaltrials.gov/study/NCT02477631
  8. https://clinicaltrials.gov/study/NCT02164253
  9. https://clinicaltrials.gov/study/NCT02191657